Neurophysiology

Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)

Wednesday, March 3, 2021 - 5:58am

Patients suffering from Complete Concentric Collapse (CCC) currently amount for at least 30% of the existing OSA patient population.

Key Points: 
  • Patients suffering from Complete Concentric Collapse (CCC) currently amount for at least 30% of the existing OSA patient population.
  • For now, these patients are contra-indicated for existing Hypoglossal Nerve Stimulation OSA therapies.
  • Nyxoah is currently conducting the BETTER SLEEP study, that aims to assess the effectiveness of the Genio system bilateral hypoglossal nerve stimulation for Complete Concentric Collapse (CCC) patients and to build clinical evidence for a potential therapeutic indication expansion.
  • We will be announcing the full results of our BETTER SLEEP study in May 2021.

Relivion® Wearable Brain Neuromodulation Technology Cleared by FDA for the Treatment of Migraine

Tuesday, March 2, 2021 - 2:01pm

Relivion is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits annually.

Key Points: 
  • Relivion is the first non-invasive multi-channel brain neuromodulation system for at home treatment of acute migraine, a debilitating neurological disease impacting 39 million people and resulting in 1.2 million emergency department visits annually.
  • This allows for the release of neurotransmitters in the brainstem and modulation of brain networks associated with control of pain.
  • The FDA marketing clearance is based on the results of a multi-center, prospective, randomized, double-blind, placebo-controlled clinical study.
  • Neuroliefs technology is currently being utilized for patients with migraine and being studied for patients with major depression.

Cognito Therapeutics to Announce New Clinical Data Evaluating Gamma Frequency Neuromodulation to Treat Alzheimer’s Disease at 2021 AD/PD Virtual Conference

Tuesday, March 2, 2021 - 1:00pm

Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today it will present for the first time, new clinical data for its digital therapeutic utilizing gamma frequency neuromodulation in Alzheimers Disease, at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), held virtually March 9-14, 2021.

Key Points: 
  • Cognito Therapeutics , a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today it will present for the first time, new clinical data for its digital therapeutic utilizing gamma frequency neuromodulation in Alzheimers Disease, at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD), held virtually March 9-14, 2021.
  • The companys licensed proprietary neuromodulation platform technology, developed by scientific founders at MIT, Professors Li-Huei Tsai and Ed Boyden is a non-invasive therapy utilizing visual and auditory stimulation to treat neurodegenerative diseases.
  • The company is based in Boston and San Francisco.
  • For more information, please visit www.cognitotx.com .

Non-Invasive Vagus Nerve Stimulation (nVNS) Enters New Stage of COVID-19 Research

Wednesday, February 24, 2021 - 12:45pm

Closing enrollment for this study is an important step to better understanding the clinical benefit of non-invasive vagus nerve stimulation (nVNS) and how it can help patients suffering from COVID-19 respiratory distress.

Key Points: 
  • Closing enrollment for this study is an important step to better understanding the clinical benefit of non-invasive vagus nerve stimulation (nVNS) and how it can help patients suffering from COVID-19 respiratory distress.
  • In fact, the most downloaded 2020 article in the Journal of Neuromodulation was The Use of Noninvasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated With COVID19: A Theoretical Hypothesis and Early Clinical Experience .
  • Research should be focused on identifying novel therapies with strong clinical rationale that can be used throughout the course of disease.
  • electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology.

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Tuesday, February 23, 2021 - 6:33pm

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

New Research Highlights the Potential of Transforming Healthcare with Mobile EEG Brain Health Assessments

Tuesday, February 23, 2021 - 6:16pm

The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.

Key Points: 
  • The studies explore rapid EEG testing in varied environments, outside of clinical settings, laying the groundwork for the future of brain health.
  • The study demonstrated that low-cost mEEG devices both conveniently and accurately measure EEG and human-event related brain potentials (ERPs) that can predict cognitive states like fatigue.
  • "Our work clearly demonstrates that mobile EEG systems can be used to quickly assess the brain state of people in any environment," says Krigolson.
  • "These results suggest a capacity to use mobile EEG technology for brain performance assessments in industry, healthcare, and personal use settings."

BrainsWay Ltd. Announces Pricing of $39,287,000 Underwritten Offering of American Depositary Shares

Tuesday, February 23, 2021 - 1:30pm

CRESSKILL, N.J. and JERUSALEM, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced it has priced an underwritten public offering of4,622,000 American Depositary Shares, each representing two ordinary shares, at an offering price of$8.50 per American Depositary Share.

Key Points: 
  • CRESSKILL, N.J. and JERUSALEM, Feb. 23, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced noninvasive treatment of brain disorders, today announced it has priced an underwritten public offering of4,622,000 American Depositary Shares, each representing two ordinary shares, at an offering price of$8.50 per American Depositary Share.
  • The gross proceeds from the offering will be approximately $39,287,000, before deducting underwriting discounts and commissions and estimated offering expenses.
  • BrainsWay has also granted the underwriters a 30-day option to purchase up to an additional693,300 American Depositary Shares on the same terms and conditions.
  • The closing of the offering is expected to take place on February 25, 2021, subject to the satisfaction of customary closing conditions.

NeuroStar® Advanced Therapy Outcomes Registry Clinical Data Published in Brain Stimulation Validates Depression Treatment Protocols

Tuesday, February 23, 2021 - 1:00pm

The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive transcranial magnetic stimulation (TMS) option for treating depression.

Key Points: 
  • The NeuroStar Outcomes Registry launched in November 2016 for the purpose of collecting and analyzing outcomes data from treatment in real-world clinical settings with Neuronetics NeuroStar Advanced Therapy, a non-drug, non-invasive transcranial magnetic stimulation (TMS) option for treating depression.
  • Since its launch, it has grown into the largest registry focused on outcomes for depression treatment.
  • Im grateful to the NeuroStar providers who contribute to the Outcomes Registry; it is research like this that informs treatment progress and advancements.
  • The research published in Brain Stimulation follows the publication of registry data in the Journal of Affective Disorders in December 2020, which suggested NeuroStar Advanced Therapy be studied and evaluated as a first-line treatment for Major Depressive Disorder.

Rhythmlink Receives FDA Clearance for New MR Conditional Electrode Line

Tuesday, February 23, 2021 - 1:00pm

Rhythmlink International, LLC has announced FDA clearance of a new product line.

Key Points: 
  • Rhythmlink International, LLC has announced FDA clearance of a new product line.
  • Sticky Pad Surface Electrodes, a line of peel and stick-on electrodes for Intraoperative Neurophysiological Monitoring (IONM) and Electroencephalography (EEG) are now FDA Cleared MR Conditional for 1.5 and 3 Tesla MRI environments.
  • View the full release here: https://www.businesswire.com/news/home/20210223005148/en/
    MR Conditional Sticky Pads are specially designed for stimulating, recording or grounding.
  • Rhythmlinks original Sticky Pad Electrode line set a new industry benchmark as the only Sticky Pad Electrode to be cleared for both recording and stimulating.

Axonics® to Report Fourth Quarter and Fiscal Year 2020 Financial Results on February 25, 2021

Monday, February 22, 2021 - 9:01pm

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.

Key Points: 
  • Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, will report fourth quarter and fiscal year 2020 financial results after the market closes on Thursday, February 25, 2021.
  • In conjunction with the release, Axonics will host a conference call at 4:30 p.m. Eastern Time.
  • Interested parties may access the live conference call by dialing 888-771-4371 (U.S.) or 847-585-4405 (International) and using passcode 50112306.
  • Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction.